A Phase I first-in-human trial of CLIC-2201, a VHH-CD22 CAR-T cell product for the treatment of relapsed/refractory CD22 positive B-cell non-Hodgkin lymphoma
A Phase I first-in-human trial of CLIC-2201, a VHH-CD22 CAR-T cell product for the treatment of relapsed/refractory CD22 positive B-cell non-Hodgkin lymphoma
CLIC-2201 的 I 期首次人体试验，CLIC-2201 是一种 VHH-CD22 CAR-T 细胞产品，用于治疗复发/难治性 CD22 阳性 B 细胞非霍奇金淋巴瘤
批准号：
453064
负责人：
Hay Kevin A
金额：
$121.49万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-09-01 至 2025-09-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Chimeric antigen receptor (CAR)-T cell therapy targeting CD19, a marker on B cell cancers, is a novel approach that has induced meaningful and durable remissions for many patients and is now considered standard of care therapy in relapsed disease. This th
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
-
批准号：466359
-
项目类别：Operating Grants
-
资助金额：$222.3万
-
财政年份：2022
-
负责人：Hay Kevin A
-
依托单位：
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
-
批准号：474613
-
项目类别：Operating Grants
-
资助金额：$55.58万
-
财政年份：2022
-
负责人：Hay Kevin A
-
依托单位：
海外基金
